AI upstart grabs $40M launch round; Sanofi backs a gene therapy player; Axsome hits a snag at the FDA
Boston AI-focused biotech DeepCure closed a $40 million Series A, according to a company announcement this morning — adding more than five times the amount of money the company had before: from $7 million raised since the company’s founding in 2018 to $47 million total.
Their goal? To have an R&D process that has drugs fully designed, synthesized and tested by AI, according to a company statement.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.